The activity of cefoperazone, a new broad-spectrum cephalosporin, was tested in vitro against 670 clinical isolates of gram-negative bacilli and gram-positive cocci. With the exception of Enterobacter spp., it inhibited the majority of all organisms tested at a concentration of 6.25 ,ug/ml. Of particular interest is its good activity against Pseudornonas aeruginosa isolates which are usually very resistant to cephalosporins. When compared with other antibiotics, it was more active than any available cephalosporin against the Enterobacteriaceae, and its activity was comparable to the investigational drugs tested. Except against Pseudomonas, cefoperazone was less active than moxalactam (LY127935 
The activity of cefoperazone, a new broad-spectrum cephalosporin, was tested in vitro against 670 clinical isolates of gram-negative bacilli and gram-positive cocci. With the exception of Enterobacter spp., it inhibited the majority of all organisms tested at a concentration of 6.25 ,ug/ml. Of particular interest is its good activity against Pseudornonas aeruginosa isolates which are usually very resistant to cephalosporins. When compared with other antibiotics, it was more active than any available cephalosporin against the Enterobacteriaceae, and its activity was comparable to the investigational drugs tested. Except against Pseudomonas, cefoperazone was less active than moxalactam (LY127935). No significant decrease in activity was noted in medium and pH variation studies. A considerable decrease in activity resulted when the size of the inoculum was increased from 105 to 107 cells/ml. The miniimal bactericidal concentrations were within one or two dilution values of the minimal inhibitory concentrations against the majority of isolates tested, except Staphylococcus aureus.
An exciting area of antimicrobial research has been the modification of naturally occurring antibiotics. Semisynthetic analogs of penicillin G have broadened the penicillin spectrum to include penicillin G-resistant Staphylococcus aureus, Enterobacteriaceae, and most recently, Pseudomonas aeruginosa. More recently, several new cephalosporin analogs and related compounds have broadened the spectrum of this class of antibiotics to include Bacteroides fragilis, some Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa. The effect of pH on drug activity was determined by adjusting the pH of Mueller-Hinton broth to 6.4, 7.2, and 8.0, using 1 N NaOH and 1 N HCI acid. Media variation was determined by using Mueller-Hinton broth, Trypticase soy broth (BBL Microbiology System), brain heart infusion broth, and nutrient broth. The effect of inoculum size was determined by using a concentration of 105 cells/ml or 107 cells/ml. The same 10 strains each of E. coli, Klebsiella spp., and P. aeruginosa were used for all of the procedures dethe procedures described above.
The minimal inhibitory concentration (MIC) was defined as the lowest concentration of drug which suppressed the growth of gram-negative bacilli and S. aureus after 18 h of incubation at 370C or suppressed the growth of S. pyogenes and S. pneumoniae after 24 h of incubation at 370C under C02. The minimal The susceptibility of P. aeruginosa isolates was determined for cefoperazone, LY127935, carbenicillin, piperacillin, mezlocillin, ticarcillin, azlocillin, and tobramycin ( Table 2 ). The most active drug was tobramycin, inhibiting 90% of the isolates at a concentration of 1.56 ,ug/ml. The activity of cefoperazone was comparable to that of piperacillin. Cefoperazone was far more active against P. aeruginosa than were the remaining drugs. Of these isolates, 15% were resistant to carbenicillin.
The activity of cefoperazone against Enterobacteriaceae was compared with LY127935, cephalothin, cefoxitin, cefamandole, mezlocillin, piperacillin, and tobramycin (Table 2 ). With the exception of LY127935, cefoperazone was the most active cephalosporin. LY127935 was consistently the most active antibiotic. Cefoperazone was as active as tobramycin against Klebsiella spp. and considerably more active than mezlocillin or piperacillin, inhibiting all Klebsiella spp. isolates at a concentration of 1.56 ,ug/ ml.
Cefoperazone was only moderately active against Enterobacter spp. compared with LY127935, which inhibited 75% of the isolates at a concentration of 6.25 ,ug/ml. The Enterobacter spp. isolates were generally resistant to the other cephalosporins tested. Of the isolates, 32% were susceptible to cefamandole. The investigational penicillins, piperacillin and mezlocillin, showed similar activity against Enterobacter spp., inhibiting over 50% of the isolates at a concentration of 50 ,g/ml. When tested against clinical isolates of S. marcescens, cefoperazone showed excellent activity, inhibiting 84% of the isolates at a concentration of 6.25 ,ug/ml. Cefoperazone was only slightly less active than LY127935 and superior to the other beta-lactam antibiotics tested against S. marcescens.
LY127935 was most active against indole-positive Proteus spp., inhibiting 90% at a concentration of 0.39 ,ug/ml. Tobramycin was slightly less active. Cefoperazone, mezlocillin, and piperacillin showed about the same degree of activity against these isolates. All the antibiotics tested were very active against P. mirabilis and E. coli isolates. Six isolates of E. coli were completely resistant to all beta-lactam antibiotics except LY127935 and cefoxitin.
The effect of inoculum size on the MICs and MBCs of cefoperazone (Table 3 ) against 10 isolates each of E. coli, Klebsiella spp., and P. aeruginosa was tested. An increase in inoculum concentration from 105 to 107 cells/ml resulted in a significant loss of activity.
These same isolates were used to determine activity in various media: Mueller-Hinton broth, Trypticase soy broth, nutrient broth, and brain heart infusion broth. There was no major effect of the various media on the MICs or MBCs of cefoperazone. When tested against these same isolates at pH 6.4, 7.2, and 8.0, the activity of cefoperazone remained constant. DISCUSSION In recent years, the substitution of various side chains on the cephalosporanic acid molecule has resulted in the development of new cephalosporins with different antibacterial spectra. Some of these newer antibiotics (cefamandole, cefoxitin, and cefuroxime) fail to inhibit P. aeruginosa (4). The major advantage of cefoperazone over these other cephalosporins is its antipseudomonal activity. In this regard, it is similar to LY127935 and HR756. Cefoperazone was more active than the antipseudomonal penicillins carbenicillin, piperacillin, ticarcillin, and mezlocillin. It was as active as piperacillin against P. aeruginosa. However, the most active antipseudomonal drug was tobramycin. Tobramycin is a less desirable agent because of its auditory toxic and nephrotoxic potential (6) . In clinical trials conducted in Japan on over 700 patients, cefoperazone has been reported to have been extremely well tolerated, with few adverse reactions. Its safety in clinical use is reported to be comparable to that of other cephalosporins (5).
Although LY127935 was the most active betalactam antibiotic against the Enterobacteriaceae, cefoperazone was the second most active cephalosporin. Especially notable are its activities against S. marcescens, Enterobacter spp., and indole-positive Proteus spp. It proved to be more potent than the investigational semisynthetic penicillins against Klebsiella spp. and Enterobacter spp. It should be noted that isolates from the patient population at this hospital are generally more resistant to multiple antibiotics VOL. 17, 1980 on June 16, 2017 by guest http://aac.asm.org/ 
